Amryt Optimistic For Year Ahead Despite Filsuvez CRL Setback
Anticipates $260m-$270m Revenue In 2022
Executive Summary
The rare disease firm hopes continued growth of key products Myalept and Mycapssa will bolster 2022 revenues as it contends with a US regulatory delay for Filsuvez.
You may also be interested in...
Top Five Takeaways From World's Largest Dermatology Conference
As the American Academy of Dermatology meeting ends in Boston, Scrip looks at some of the key data presented at the congress covering the latest advances in the hot area of atopic dermatitis, alopecia and butterfly skin.
Amryt Due For Oral Explanation At EMA For Epidermolysis Bullosa Gel Filsuvez
Amryt Pharmaceuticals is set to appear before the European Medicines Agency to explain why its treatment for patients with epidermolysis bullosa merits EU-wide approval. The drug was recently rejected in the US.
US FDA’s 2022 Novel Agent Actions Suggest Acceleration In Use Of Complete Response Letters
COVID does not appear to be a driving factor, and letters are split almost equally between clinical and quality concerns.